Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human TNFSF10 Antikörper:
anti-Mouse (Murine) TNFSF10 Antikörper:
anti-Rat (Rattus) TNFSF10 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal TNFSF10 Primary Antibody für IHC (p), WB - ABIN252480
Müller, Raftery, Kather, Giese, Schönrich: Frontline: Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus. in European journal of immunology 2004
Show all 7 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für FACS - ABIN2689127
Marsters, Pitti, Donahue, Ruppert, Bauer, Ashkenazi: Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. in Current biology : CB 1997
Show all 6 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für FACS - ABIN2689130
Mariani, Matiba, Armandola, Krammer: Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. in The Journal of cell biology 1997
Show all 5 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für BCA, BR - ABIN1176947
Kayagaki, Yamaguchi, Nakayama, Kawasaki, Akiba, Okumura, Yagita: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. in Journal of immunology (Baltimore, Md. : 1950) 1999
Show all 5 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für WB - ABIN1169389
Huber, Fais, Iero, Lugini, Canese, Squarcina, Zaccheddu, Colone, Arancia, Gentile, Seregni, Valenti, Ballabio, Belli, Leo, Parmiani, Rivoltini: Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. in Gastroenterology 2005
Show all 4 Pubmed References
Mouse (Murine) Monoclonal TNFSF10 Primary Antibody für FACS, WB - ABIN2689128
Mariani, Krammer: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. in European journal of immunology 1998
Show all 4 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für FACS - ABIN1383744
Herbeuval, Boasso, Grivel, Hardy, Anderson, Dolan, Chougnet, Lifson, Shearer: TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. in Blood 2005
Show all 3 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für FACS - ABIN4897836
Kalb, Glaser, Stary, Koszik, Stingl: TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-?-mediated antitumor reactivity. in Journal of immunology (Baltimore, Md. : 1950) 2012
Show all 3 Pubmed References
Human Monoclonal TNFSF10 Primary Antibody für ELISA, FACS - ABIN4361856
Liabakk, Sundan, Torp, Aukrust, Frøland, Espevik: Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. in Journal of immunological methods 2001
Show all 2 Pubmed References
Human Polyclonal TNFSF10 Primary Antibody für IF (p), IHC (p) - ABIN673494
Fang, Zhang, Qi, Fan, Luo, Liu, Tan: Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells. in PLoS ONE 2014
Show all 2 Pubmed References
DR5 (zeige TNFRSF10B Antikörper)-Cbl-b/c-Cbl (zeige CBL Antikörper)-TRAF2 (zeige TRAF2 Antikörper) complex inhibited TRAIL-induced apoptosis by promoting TRAF2 (zeige TRAF2 Antikörper)-mediated polyubiquitination of caspase-8 (zeige CASP8 Antikörper) in gastric cancer cells.
We found that the combination of alpha-mangostin with TRAIL induced apoptosis of SAS (zeige TSPAN31 Antikörper) cells through the mitochondrial pathway via activation of caspase-9 (zeige CASP9 Antikörper) and -3/7, following release of cytochrome c (zeige CYCS Antikörper). This apoptosis was induced by S/G2 (zeige STRN3 Antikörper)/M-phase arrest. Immunopositivity for c-Myc (zeige MYC Antikörper) was observed in the cytoplasm of tumor cells in 16 (40%) of the 40 cases of human oral squamous cell carcinoma (HOSCC).
this study characterized in juvenile systemic lupus erythematosus a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL (zeige FASL Antikörper), notably in patients with active disease and with nephritis.
Notch1 (zeige NOTCH1 Antikörper) activation also suppressed A549 cell apoptosis by inhibiting the PI3K (zeige PIK3CA Antikörper)/pAkt (zeige AKT1 Antikörper) pathway and activating the caspase-3 (zeige CASP3 Antikörper) pathway in cooperation with TRAIL. Combining Notch1 (zeige NOTCH1 Antikörper) signal with TRAIL inhibited PI3K (zeige PIK3CA Antikörper), phosphorylated Akt (zeige AKT1 Antikörper) and phosphorylated STAT3 (zeige STAT3 Antikörper) expressions.
we show that executioner caspase (zeige CASP3 Antikörper) activation of the apoptotic nuclease (zeige DCLRE1C Antikörper) CAD/DFF40 (zeige DFFB Antikörper) is essential for TRAIL-induced mutations in surviving cells. As exposure to chemotherapy drugs also activates apoptotic caspases and presumably CAD (zeige CAD Antikörper), we hypothesized that these pathways may also contribute to the mutagenesis induced by conventional chemotherapy drugs, perhaps augmenting the mutations that arise from direct DNA damage
Cultured HCN-2 (zeige HCN2 Antikörper) neurons were incubated at different times with GITRL (zeige TNFSF18 Antikörper) and/or TRAIL, and thereafter nucleic acid and protein expression were measured. HCN-2 (zeige HCN2 Antikörper) cells do not express GITRL (zeige TNFSF18 Antikörper) mRNA, but the latter is induced after treatment with TRAIL. Cells did not express the GITRL (zeige TNFSF18 Antikörper) receptor GITR (zeige TNFRSF18 Antikörper) mRNA, neither in control cultures, nor after treatment with TRAIL. TRAIL, when associated to GITRL (zeige TNFSF18 Antikörper), exerted additive toxic effects.
OPG (zeige TNFRSF11B Antikörper) and OPG (zeige TNFRSF11B Antikörper)/TRAIL ratio expression were significantly increased in rheumatoid arthritis patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG (zeige TNFSF11 Antikörper) ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL (zeige TNFSF11 Antikörper) and TRAIL expression.
DR5 (zeige TNFRSF10B Antikörper) has a dual role in death and survival signaling, which results in TRAIL resistance in cancer cells.
Dynamin (zeige DNM1 Antikörper) isoforms differentially regulate the endocytosis and apoptotic signaling downstream of TRAIL-death receptor (TRAIL-DR) complexes in cancer cells. TRAIL stimulation activates ryanodine receptor (zeige RYR3 Antikörper)-mediated calcium release from endoplasmic reticulum stores, leading to calcineurin-mediated dephosphorylation and activation of Dyn1 (zeige DNM1L Antikörper), TRAIL-DR endocytosis, and increased resistance to TRAIL-induced apoptosis.
These results suggest that the FasL (zeige FASL Antikörper) -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease.
Isolated highly-pure population of DcR2 (zeige TNFRSF10D Antikörper)-positive renal tubular epithelial cells was isolated by MACS, which was confirmed to comprise of active senescent RTECs based on the cell cycle phase.
In this study, the authors identified by gene expression profiling that microgravity induces high levels of TRAIL expression in murine preosteoclast cells in the absence of RANKL (zeige TNFSF11 Antikörper) stimulation compared to ground based cultures.
Data suggest that the CXCL9 (zeige CXCL9 Antikörper)-CXCR3 (zeige CXCR3 Antikörper) axis plays a pivotal role in the liver-specific distribution of TRAIL+ NK cells in mice.
Tnfsf10 expression is increased in eosinophilic esophagitis. Tnfsf10(-/-) mice were largely protected from esophageal fibrosis and eosinophilic inflammation.
Diabetes significantly increased OPG (zeige TNFSF11 Antikörper) and the OPG (zeige TNFSF11 Antikörper)/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG (zeige TNFSF11 Antikörper) and reduced TRAIL expression, thus increasing cardiac OPG (zeige TNFSF11 Antikörper)/TRAIL ratio.
TRAIL can promote angiogenesis following hindlimb ischemia in vivo via NOX4 (zeige NOX4 Antikörper)/eNOS (zeige NOS3 Antikörper)/nitric oxide signaling.
Study reports that loss of the Opg (zeige TNFSF11 Antikörper) gene results in deterioration of abdominal aortic aneurysms (AAA (zeige AAAS Antikörper)), possibly through involvement of TRAIL in smooth muscle actin (SMA (zeige SMN1 Antikörper))-positive cells and myofibroblasts.
PARP1 (zeige PARP1 Antikörper) acts as a prominent upstream regulator of high mobility group box 1 (zeige HMGB1 Antikörper)-mediated autophagy and maintains a homeostatic balance between apoptosis and autophagy, which provides new insight into the mechanism of TNFSF10 resistance
Data suggest that Socs3 (suppressor of cytokine signaling 3 (zeige SOCS3 Antikörper)) plays critical negative role in regulation of Trail expression in endoplasmic reticulum stress in macrophages via Jun N-terminal kinase (zeige MAPK8 Antikörper)/AP-1 (zeige JUN Antikörper) transcription factor signaling.
These findings indicate that acute fasting enhances TRAIL-mediated liver natural killer cell activity against neoplastic cells through upregulation of heat shock protein 70 (zeige HSP70 Antikörper).
Data suggest forkhead box protein O1 (FoxO1 (zeige FOXO1 Antikörper)) involvement in the regulation of TNF-related apoptosis-inducing ligand TRAIL and Fas ligand FasL (zeige FASL Antikörper) expression during follicular atresia.
The chromosomal location of the porcine TNFSF10 gene was determined by FISH of a specific BAC clone to metaphase chromosomes The chromosomal location of the porcine TNFSF10 gene was determined by FISH of a specific BAC clone to metaphase chromosomes.
xTRAIL1 can cause apoptosis, probably mediated through xDR-Ms, in larval red blood cells, but may not kill adult RBCs, presumably owing to PKC (zeige PKC Antikörper) activation, as part of the mechanism for RBC (zeige CACNA1C Antikörper) switching
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
, TNF-related apoptosis inducing ligand TRAIL
, chemokine tumor necrosis factor ligand superfamily member 10
, tumor necrosis factor (ligand) family, member 10
, tumor necrosis factor apoptosis-inducing ligand splice variant delta
, tumor necrosis factor ligand superfamily member 10
, TNF-related apoptosis inducing ligand
, TNF-related apoptosis-inducing ligand
, tumor necrosis factor-related apoptosis-inducing ligand
, TNF-related apoptosis-inducing ligand 1
, tumor necrosis factor related apoptosis inducing ligand 1
, tumor necrosis factor (ligand) superfamily, member 10 like 2
, tumor necrosis factor (ligand) superfamily, member 10
, tumor necrosis factor ligand 6A
, tumor necrosis factor superfamily member 10